• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Medpace Holdings Inc. (Amendment)

    9/22/23 6:10:57 AM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $MEDP alert in real time by email
    SC 13D/A 1 d541174dsc13da.htm SC 13D/A SC 13D/A

     

     

    United States

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    (Rule 13d-101)

    Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and

    Amendments Thereto Filed Pursuant to § 240.13d-2(a)

    Under the Securities Exchange Act of 1934

    (Amendment No. 18)*

     

     

    Medpace Holdings, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    58506Q109

    (CUSIP Number)

    August J. Troendle

    c/o Medpace Holdings, Inc.

    5375 Medpace Way

    Cincinnati, OH 45227

    Tel: (513) 579-9911

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    September 20, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


     1   

     NAMES OF REPORTING PERSONS

     

     August J. Troendle

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     PF

     5  

     Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     806,643

        8  

     SHARED VOTING POWER

     

     5,914,947

        9  

     SOLE DISPOSITIVE POWER

     

     806,643

       10  

     SHARED DISPOSITIVE POWER

     

     5,914,947

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     7,135,606

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     23.0%

    14  

     TYPE OF REPORTING PERSON

     

     IN


     1   

     NAMES OF REPORTING PERSONS

     

     Medpace Investors, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     OO

     5  

     Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     5,914,947

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     5,914,947

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,914,947

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     19.1%

    14  

     TYPE OF REPORTING PERSON

     

     OO (Limited liability company)


    This Amendment No. 18 to the Schedule 13D (this “Amendment No. 18”) amends and supplements the Statement on Schedule 13D filed with the United States Securities and Exchange Commission on August 26, 2016, as amended by Amendment No. 1 filed on August 8, 2018, Amendment No. 2 filed on October 2, 2018, Amendment No. 3 filed on February 6, 2019, Amendment No. 4 filed on August 5, 2019, Amendment No. 5 filed on August 7, 2019, Amendment No. 6 filed on August 15, 2019, Amendment No. 7 filed on September 17, 2019, Amendment No. 8 filed on May 8, 2020, Amendment No. 9 filed on July 31, 2020, Amendment No. 10 filed on August 14, 2020, Amendment No. 11 filed on December 21, 2020, Amendment No. 12 filed on April 21, 2021, Amendment No. 13 filed on September 1, 2021, Amendment No. 14 filed on December 23, 2021, Amendment No. 15 filed on July 6, 2022, Amendment No. 16 filed on September 13, 2022, and Amendment No. 17 filed September 21, 2022 (collectively, the “Statement”), relating to the common stock (the “Common Stock”), of Medpace Holdings, Inc., a Delaware corporation (the “Issuer”). Capitalized terms used herein without definition shall have the meaning set forth in the Statement.

    Item 4. Purpose of Transaction

    Item 4 of the Statement is amended and restated in its entirety as follows:

    The Reporting Persons acquired the securities described in this Schedule 13D for investment purposes and they intend to review their investments in the Issuer on a continuing basis. Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons’ review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer’s business, financial condition, operations and prospects; price levels of the Issuer’s securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments.

    The Reporting Persons may, at any time and from time to time, acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions whether pursuant to or outside of Rule 10b5-1 trading plans. In this regard, the Reporting Persons have entered into and amended, as the case may be, Rule 10b5-1 trading plans with respect to acquiring or selling Issuer securities. The Reporting Persons may in the future enter into and/or amend Rule 10b5-1 trading plans with respect to the acquisition or sale of Issuer securities involving amounts greater than or less than one percent of the Issuer’s outstanding common stock. The Reporting Persons also may attempt to pledge shares pursuant to margin, loan and other security agreements, subject to compliance with the Company’s Insider Trading Compliance Policy. In addition, the Reporting Persons including Dr. Troendle in his positions as Chief Executive Officer and Chairman of the Board, may engage in discussions with management, the Board, and shareholders of the Issuer and other relevant parties or encourage such persons to consider or explore extraordinary corporate transactions, such as: a merger; sales or acquisitions of assets or businesses; changes to the capitalization or dividend policy of the Issuer; or other material changes to the Issuer’s business or corporate structure.

    Other than as described above, none of the Reporting Persons currently has any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)–(j) of Schedule 13D, although, depending on the factors discussed herein, the Reporting Persons may change their purpose or formulate different plans or proposals with respect thereto at any time.

    Item 5. Interest in Securities of the Issuer

    Items 5(a) - (b) of the Statement are amended and restated in their entirety as follows:

    (a) - (b): See Items 7 – 13 of the cover pages above.

    Item 5(c) of the Statement is amended and supplemented by inserting the following information:

    (c): On May 1, 2023, Medpace Investors, LLC (“MPI”) entered into a written stock selling plan in accordance with Rule 10b5-1 (the “May 2023 MPI Plan”). The May 2023 MPI Plan contemplated the sale of up to 500,000 shares. MPI has sold shares in open market transactions pursuant to the May 2023 MPI Plan between September 18, 2023 and the date of this filing as follows:

     

    Trade Date

       Shares Sold      Price Per
    Share
     

    09/18/2023

         11,629      $ 272.20  (1) 

    09/18/2023

         14,023      $ 272.96  (2) 

    09/18/2023

         1,006      $ 273.91 (3) 

    09/18/2023

         5,023      $ 275.27  (4) 

    09/18/2023

         3,155      $ 276.06  (5) 

    09/18/2023

         12,938      $ 277.10 (6) 

    09/18/2023

         5,609      $ 278.16 (7) 

    09/18/2023

         2      $ 278.665  

    09/19/2023

         21,460      $ 255.48 (8) 


    09/19/2023

         35,845      $ 256.21 (9) 

    09/19/2023

         17,280      $ 257.10 (10) 

    09/19/2023

         3,736      $ 258.065 (11) 

    09/19/2023

         6,276      $ 259.29 (12) 

    09/19/2023

         3,224      $ 260.07 (13) 

    09/19/2023

         6,772      $ 261.25 (14) 

    09/19/2023

         4,212      $ 262.22 (15) 

    09/19/2023

         3,756      $ 263.25 (16) 

    09/19/2023

         3,129      $ 264.36 (17) 

    09/19/2023

         11,815      $ 265.41 (18) 

    09/19/2023

         9,194      $ 266.21 (19) 

    09/19/2023

         6,368      $ 267.26 (20) 

    09/19/2023

         3,491      $ 268.19 (21) 

    09/19/2023

         338      $ 269.22 (22) 

    09/19/2023

         483      $ 271.25 (23) 

    09/20/2023

         1,684      $ 253.79 (24) 

    09/20/2023

         25,680      $ 254.78 (25) 

    09/20/2023

         22,273      $ 255.58 (26) 

    09/20/2023

         13,330      $ 256.46 (27) 

    09/20/2023

         2,686      $ 257.44 (28) 

    09/21/2023

         4,410      $ 240.40 (29) 

    09/21/2023

         2,902      $ 241.40 (30) 

    09/21/2023

         2,952      $ 242.45 (31) 

    09/21/2023

         13,175      $ 243.46 (32) 

    09/21/2023

         16,574      $ 244.35 (33) 

    09/21/2023

         12,375      $ 245.37 (34) 

    09/21/2023

         6,539      $ 246.20 (35) 

    09/21/2023

         508      $ 247.48 (36) 

    09/21/2023

         372      $ 248.29 (37) 

    09/21/2023

         1,462      $ 249.80 (38) 

    09/21/2023

         386      $ 251.58  

     

    (1)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $271.505 to $272.485. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (2)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $272.505 to $273.47. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (3)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $273.50 to $274.475. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (4)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $274.57 to $275.53. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (5)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $275.645 to $276.475. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (6)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $276.645 to $277.635. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (7)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $277.64 to $278.60. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (8)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $254.74 to $255.735. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (9)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $255.74 to $256.735. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.


    (10)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $256.74 to $257.725. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (11)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $257.74 to $258.73. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (12)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $258.755 to $259.73. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (13)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $259.75 to $260.73. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (14)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $260.77 to $261.76. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (15)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $261.77 to $262.755. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (16)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $262.78 to $263.765. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (17)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $263.80 to $264.78. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (18)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $264.81 to $265.80. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (19)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $265.83 to $266.81. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (20)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $266.85 to $267.84. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (21)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $267.85 to $268.66. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (22)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $268.91 to $269.32. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (23)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $270.5775 to $271.42. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (24)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $253.07 to $254.06. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (25)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $254.07 to $255.06. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (26)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $255.07 to $256.065. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (27)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $256.07 to $257.06. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (28)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $257.08 to $257.935. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (29)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $239.77 to $240.75. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (30)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $240.775 to $241.73. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.


    (31)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $241.79 to $242.755. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (32)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $242.81 to $243.80. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (33)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $243.81 to $244.79. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (34)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $244.87 to $245.86. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (35)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $245.88 to $246.76. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (36)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $246.90 to $247.80. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (37)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $248.15 to $248.39. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    (38)

    The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $249.72 to $250.37. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

    On September 21, 2023, MPI terminated the May 2023 MPI Plan pursuant to its terms. No additional transactions have taken place under the May 2023 MPI Plan other than the transactions set forth in this Amendment No. 18.

    On February 20, 2023, MPI entered into a written stock selling plan in accordance with Rule 10b5-1 (the “February 2023 MPI Plan,” and together with the May 2023 MPI Plan, the “2023 MPI Plans”). The February 2023 MPI Plan contemplated the sale of up to 250,000 shares. No transactions pursuant to the February 2023 MPI Plan have been executed in the last 60 days and the February 2023 MPI Plan has terminated in accordance with its terms.

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

    Item 6 of the Statement is amended and supplemented as follows:

    Item 5 above summarizes certain provisions of the 2023 MPI Plans and is incorporated herein by reference. Copies of the 2023 MPI Plans are attached as Exhibits 3.1 and 3.2 hereto, and are incorporated by reference.

    Except as set forth herein and in the Statement, none of the Reporting Persons has any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including, but not limited to, any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.


    Item 7. Materials to be Filed as Exhibits

     

    Exhibit
    Number

      

    Description

    1   

    Joint Filing Agreement*

    2    Registration Rights Agreement*
    3.1    May 2023 Rule 10b5-1 Stock Trading Plan of Medpace Investors, LLC
    3.2    February 2023 Rule 10b5-1 Stock Trading Plan of Medpace Investors, LLC

     

    *

    Filed in the Statement.


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: September 22, 2023

     

    /s/ August J. Troendle

    August J. Troendle
    Medpace Investors, LLC

    /s/ August J. Troendle

    Name: August J. Troendle
    Title: Sole Manager


    Rule 10b5-l Trading Plan

    Get the next $MEDP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MEDP

    DatePrice TargetRatingAnalyst
    4/22/2025Outperform → Mkt Perform
    William Blair
    4/14/2025$328.00Buy → Hold
    TD Cowen
    3/24/2025$330.00Market Perform
    Leerink Partners
    10/23/2024$413.00 → $349.00Outperform → Neutral
    Robert W. Baird
    10/14/2024Buy
    Redburn Atlantic
    9/27/2024$420.00 → $350.00Buy → Neutral
    UBS
    9/25/2024$415.00 → $345.00Buy → Hold
    Jefferies
    8/1/2024$415.00Hold
    Truist
    More analyst ratings

    $MEDP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Medpace Holdings, Inc. Reports First Quarter 2025 Results

      Revenue of $558.6 million in the first quarter of 2025 increased 9.3% from revenue of $511.0 million for the comparable prior-year period, representing a backlog conversion rate of 19.2%. Net new business awards were $500.0 million in the first quarter of 2025, representing a decrease of 18.8% from net new business awards of $615.6 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.90x. First quarter of 2025 GAAP net income was $114.6 million, or $3.67 per diluted share, versus GAAP net income of $102.6 million, or $3.20 per diluted share, for the comparable prior-year period. Net income margin was 20.5% and 20.1% for the first quarter of 2025

      4/21/25 4:15:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Medpace Holdings, Inc. to Report First Quarter 2025 Financial Results on April 21, 2025

      Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its first quarter 2025 financial results after the market close on Monday, April 21, 2025. The Company will host a conference call the following morning, Tuesday, April 22, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used

      3/18/25 4:05:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Results

      Revenue of $536.6 million in the fourth quarter of 2024 increased 7.7% from revenue of $498.4 million for the comparable prior-year period, representing a backlog conversion rate of 18.3%. Net new business awards were $529.7 million in the fourth quarter of 2024, representing a decrease of 13.8% from net new business awards of $614.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.99x. Fourth quarter of 2024 GAAP net income was $117.0 million, or $3.67 per diluted share, versus GAAP net income of $78.3 million, or $2.46 per diluted share, for the comparable prior-year period. Net income margin was 21.8% and 15.7% for the fourth quarter of

      2/10/25 4:15:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    SEC Filings

    See more
    • SEC Form 8-K filed by Medpace Holdings Inc.

      8-K - Medpace Holdings, Inc. (0001668397) (Filer)

      5/16/25 5:11:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 144 filed by Medpace Holdings Inc.

      144 - Medpace Holdings, Inc. (0001668397) (Subject)

      4/24/25 2:13:57 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 10-Q filed by Medpace Holdings Inc.

      10-Q - Medpace Holdings, Inc. (0001668397) (Filer)

      4/22/25 4:02:48 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel & Corp. Secy. Ewald Stephen P bought $652 worth of shares (2 units at $326.11), increasing direct ownership by 0.01% to 13,343 units (SEC Form 4)

      4 - Medpace Holdings, Inc. (0001668397) (Issuer)

      2/28/25 4:39:05 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Zander Dani S.

      4 - Medpace Holdings, Inc. (0001668397) (Issuer)

      5/20/25 4:59:16 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Mccarthy Cornelius P. Iii

      4 - Medpace Holdings, Inc. (0001668397) (Issuer)

      5/20/25 4:51:25 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Kraft Robert O.

      4 - Medpace Holdings, Inc. (0001668397) (Issuer)

      5/20/25 4:45:08 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    Leadership Updates

    Live Leadership Updates

    See more
    • Medpace Holdings, Inc. Announces Senior Leadership Changes

      Appointment of Jesse Geiger as President and Kevin Brady as Chief Financial Officer Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced the appointment of Jesse Geiger as president and Kevin Brady as chief financial officer, effective August 1, 2021. August Troendle will continue to serve as Medpace's chairman and chief executive officer. Geiger joined Medpace in 2007 as corporate controller and became chief financial officer in 2011. In 2014, Geiger expanded his role to include chief operating officer of laboratory operations. Geiger will continue to report to August Troendle. The newly created position of president will allow Troendle to continue to focus on the overall lon

      7/26/21 4:15:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Medpace downgraded by William Blair

      William Blair downgraded Medpace from Outperform to Mkt Perform

      4/22/25 10:17:27 AM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Medpace downgraded by TD Cowen with a new price target

      TD Cowen downgraded Medpace from Buy to Hold and set a new price target of $328.00

      4/14/25 8:14:21 AM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Leerink Partners initiated coverage on Medpace with a new price target

      Leerink Partners initiated coverage of Medpace with a rating of Market Perform and set a new price target of $330.00

      3/24/25 8:40:00 AM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Medpace Holdings Inc. (Amendment)

      SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)

      3/8/24 4:28:58 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by Medpace Holdings Inc. (Amendment)

      SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)

      2/28/24 5:04:01 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by Medpace Holdings Inc. (Amendment)

      SC 13G/A - Medpace Holdings, Inc. (0001668397) (Subject)

      2/13/24 5:09:38 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $MEDP
    Financials

    Live finance-specific insights

    See more
    • Medpace Holdings, Inc. Reports First Quarter 2025 Results

      Revenue of $558.6 million in the first quarter of 2025 increased 9.3% from revenue of $511.0 million for the comparable prior-year period, representing a backlog conversion rate of 19.2%. Net new business awards were $500.0 million in the first quarter of 2025, representing a decrease of 18.8% from net new business awards of $615.6 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.90x. First quarter of 2025 GAAP net income was $114.6 million, or $3.67 per diluted share, versus GAAP net income of $102.6 million, or $3.20 per diluted share, for the comparable prior-year period. Net income margin was 20.5% and 20.1% for the first quarter of 2025

      4/21/25 4:15:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Medpace Holdings, Inc. to Report First Quarter 2025 Financial Results on April 21, 2025

      Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its first quarter 2025 financial results after the market close on Monday, April 21, 2025. The Company will host a conference call the following morning, Tuesday, April 22, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used

      3/18/25 4:05:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Results

      Revenue of $536.6 million in the fourth quarter of 2024 increased 7.7% from revenue of $498.4 million for the comparable prior-year period, representing a backlog conversion rate of 18.3%. Net new business awards were $529.7 million in the fourth quarter of 2024, representing a decrease of 13.8% from net new business awards of $614.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.99x. Fourth quarter of 2024 GAAP net income was $117.0 million, or $3.67 per diluted share, versus GAAP net income of $78.3 million, or $2.46 per diluted share, for the comparable prior-year period. Net income margin was 21.8% and 15.7% for the fourth quarter of

      2/10/25 4:15:00 PM ET
      $MEDP
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care